
    
      The conditioning regimen consists of alemtuzumab (Campath-1H), clofarabine, melphalan, and
      VMAT-delivered low-dose TBI with boosted marrow irradiation. Additional graft-versus-host
      disease prophylaxis consists of mycophenolate mofetil and cyclosporine.
    
  